摘要
To the Editor: On March 9, 2018, a 31-year-old woman presented with liver dysfunction after thyroid cancer surgery. She was physically healthy;had no chronic diseases, such as hypertension and diabetes;had no history of infectious diseases, such as hepatitis and tuberculosis;had no history of drugs, food allergies, smoking, and alcohol consumption;and presented no obvious complaints during the disease course. B-ultrasound in the physical examination 3 years prior showed “left thyroid-occupying position.” On February 5, 2018, she had undergone surgery at our hospital. Laboratory findings on February 6, 2018 revealed white blood cells (WBCs) 9.06 × 10^9/L (3.50–9.50 × 10^9/L);neutrophils (NEs) 5.66 × 10^9/L (1.80–6.30 × 10^9/L);triiodothyronine (T3) 0.94 (0.80–2.00) ng/mL;thyroxine (T4) 6.4 (5.1–14.1)μg/dL;free T3 (FT3) 3.95 (3.10–6.80) pmol/L;free T4 (FT4) 15.57 (12.00–22.00) pmol/L;thyroid-stimulating hormone (TSH) 2.56 (0.27–4.20) mU/L;thyroid peroxidase antibody (TPOAb) 8.2 (0–34.0) IU/mL;thyroglobulin antibody (TgAb)<10 (≤115) IU/mL;total bilirubin (T-BIL) 21.5 (5.0–22.0)μmol/L;direct bilirubin (D-BIL) 6.3 (0–10.2)μmol/L;alanine transaminase (ALT) 27.5 (7.0–40.0) U/L;aspartate transaminase (AST) 22.7 (13.0–35.0) U/L;and alkaline phosphatase (ALP), 48.9 (35.0–100.0) U/L. Hepatitis C antibody, hepatitis B surface antigen, and hepatitis B core antibody immunoglobulin M tested negative. On February 7, 2018, intra-operative pathology during left thyroidectomy indicated micro-papillary carcinoma. On February 11, 2018, she was discharged and prescribed levothyroxine tablets A (LTA;Merck KGaA, Darmstadt, Germany) 100 μg and calcium carbonate D3 tablets (CC-D3;Pfizer, China) 600 mg once daily.
